Target intelligence / Profile preview

MicroRNA-222 (miR-222)

Target
miR-222
Molecular classification
MicroRNA, Non-coding RNA, Post-transcriptional regulator, Small RNA (20-24 nucleotides)
01

Overview

MicroRNA-222 (miR-222) is a small non-coding RNA molecule of 20-24 nucleotides encoded by the MIR222 gene located on chromosome X. It functions as a post-transcriptional regulator of gene expression by binding to complementary sequences in the 3'-untranslated regions of target messenger RNAs, leading to translational repression or mRNA degradation. MicroRNA-222 exists as multiple isoforms (isomiRs) varying in length from 21 to 25 nucleotides, with different isoforms showing distinct subcellular localization patterns and biological functions. The longer isoforms (>23 nucleotides) are enriched in the nucleus and associated with apoptosis induction, while various length isoforms demonstrate anti-proliferative effects. MicroRNA-222 regulates multiple cellular processes including cell cycle progression, proliferation, apoptosis, invasion, migration, and differentiation through targeting genes such as p27, MMP1, SOD2, and MEF2C. Its role in cancer is complex and context-dependent, functioning as a tumor suppressor in prostate cancer and oral squamous cell carcinoma while showing different effects in other cancer types. It is also implicated in cardiovascular disease and vascular smooth muscle cell proliferation. The therapeutic potential and biomarker utility of miR-222 are being actively investigated, though isoform-specific effects and context-dependent functions present significant challenges for clinical translation.

Other names
miR-222-3phsa-miR-222MIRN222HSA-MIR-222MIR222
02

Mechanism of action

MicroRNA-222 regulates target genes through both direct targeting of mRNA 3'-untranslated regions (cis-regulatory mechanism) via imperfect base pairing and indirect mechanisms (trans-regulatory mechanism) by controlling gene expression through targeting upstream regulators. This leads to translational repression or mRNA degradation. Additionally, longer miR-222 isoforms (>23 nucleotides) show dramatic nuclear enrichment and may participate in transcriptional regulation (non-canonical mechanism through nuclear localization).

03

Biological functions

Post-transcriptional gene regulationCell cycle regulationCell proliferation controlApoptosis regulationCell invasion and migrationCell differentiation (including adipogenesis)Vascular smooth muscle cell proliferationDNA damage response
04

Disease associations

Cancer (multiple types including prostate cancer, oral tongue squamous cell carcinoma, glioblastoma, papillary thyroid carcinoma, diffuse large B-cell lymphoma)Castration-resistant prostate cancerCardiovascular diseaseVascular proliferative disorders
05

Safety considerations

Isoform-specific effects: Different length variants (21-25 nucleotides) have distinct and potentially opposing biological functions, complicating therapeutic designContext-dependent functions: miR-222 shows tumor-suppressive effects in some cancer types but oncogenic effects in othersOff-target effects: Single microRNAs can regulate hundreds of genes, potentially causing unintended consequencesConflicting literature: Studies using different miR-222 mimics (particularly the canonical 21-nucleotide form versus longer isoforms) report contradictory effects on apoptosisSpecies-specific annotation differences: The canonical miR-222 sequence varies between species, affecting experimental design and interpretationmiRBase annotation changes: The canonical definition changed in version 10 (August 2007) from the +CUC containing sequence to the shorter 21-nucleotide sequence
06

Interacting drugs

MicroRNA mimics (synthetic oligonucleotides matching miR-222 sequence)

2 more in the full profile.

07

Biomarkers

Cancer biomarker (particularly for prostate cancer prognosis)Cardiovascular disease biomarkerPredictor of progression to castration-resistant prostate cancer (low expression predicts shorter progression time)Risk of recurrence marker in papillary thyroid carcinomaPotential biomarker in small and medium/large extracellular vesicles

Beyond the preview

Go deeper on MicroRNA-222 (miR-222).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA-222 (miR-222).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call